Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ADCs - Overcoming Analytical Challenges in Next-Gen Cancer Therapeutics | Contract Pharma

What are you searching for?

Sign in
White Papers / Tech Papers

ADCs – Overcoming Analytical Challenges in Next-Gen Cancer Therapeutics

Antibody-Drug Conjugates (ADCs) represent a revolutionary approach in cancer treatment.

Released By Solvias

Antibody-Drug Conjugates (ADCs) represent a revolutionary approach in cancer treatment by combining the selectivity of monoclonal antibodies with the potency of cytotoxic drugs. However, the unique complexity of ADCs introduces a range of analytical challenges. This white paper explores these critical challenges, focusing on the characterization, stability, and potency of each ADC component. It highlights the need for comprehensive and customized analytical strategies to ensure the safety, efficacy, and consistency of these therapeutics. From ensuring antibody integrity and linker stability to accurately assessing payload potency and drug-to-antibody ratios, each step demands precision to navigate the intricate pathways of ADC development.

Download White Papers / Tech Papers Now

Download White Papers / Tech Papers Now

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters